Recent Updates — LKFT

Lakefront Biotherapeutics NV completed its share repurchase program announced on June 9, 2026, by purchasing 107,804 shares between October 12 and October 16, 2026. The company spent a total of €2,854,365.69 at an average price of €26.48 per share across multiple European exchanges. As of market close on October 16, Lakefront holds 1,985,157 of its own ordinary shares. The filing discloses the final execution details of this discretionary mandate to an independent financial intermediary. Lakefront Biotherapeutics is a clinical-stage biotechnology company developing immunology and inflammation treatments.

Lakefront Biotherapeutics completed the sale of its early-stage cell therapy pipeline, including multi-targeting and armed CAR-T constructs, to Armed Cell Therapeutics BV. The transaction includes an upfront payment of €8 million and potential milestone payments totaling up to $230 million, along with a low-single-digit royalty on future sales. This divestiture substantially completes the company's previously announced wind-down of legacy cell therapy activities. Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.